These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1041 related articles for article (PubMed ID: 16894619)

  • 1. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.
    Allgulander C; Mangano R; Zhang J; Dahl AA; Lepola U; Sjödin I; Emilien G;
    Hum Psychopharmacol; 2004 Aug; 19(6):387-96. PubMed ID: 15303242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A; Korotzer A; Gommoll C; Li D
    Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adinazolam sustained-release treatment of panic disorder: a double-blind study.
    Davidson JR; Beitman B; Greist JH; Maddock RJ; Lewis CP; Sheridan AQ; Carter C; Krishnan KR; Liebowitz MR; Haack DG
    J Clin Psychopharmacol; 1994 Aug; 14(4):255-63. PubMed ID: 7962681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study.
    Davidson J; Rothbaum BO; Tucker P; Asnis G; Benattia I; Musgnung JJ
    J Clin Psychopharmacol; 2006 Jun; 26(3):259-67. PubMed ID: 16702890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients.
    Nemeroff CB; Thase ME;
    J Psychiatr Res; 2007; 41(3-4):351-9. PubMed ID: 16165158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder.
    Pollack M; Mangano R; Entsuah R; Tzanis E; Simon NM; Zhang Y
    Psychopharmacology (Berl); 2007 Oct; 194(2):233-42. PubMed ID: 17589833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacy.
    Carter CS; Fawcett J; Hertzman M; Papp LA; Jones W; Patterson WM; Swinson RP; Weise CC; Maddock RJ; Denahan AQ
    J Clin Psychiatry; 1995 May; 56(5):202-10. PubMed ID: 7737960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
    Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA;
    J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study.
    Perna G; Bertani A; Caldirola D; Smeraldi E; Bellodi L
    Pharmacopsychiatry; 2001 May; 34(3):85-90. PubMed ID: 11434404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.
    Simon JS; Aguiar LM; Kunz NR; Lei D
    J Psychiatr Res; 2004; 38(3):249-57. PubMed ID: 15003430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose venlafaxine treatment in panic disorder.
    Papp LA; Sinha SS; Martinez JM; Coplan JD; Amchin J; Gorman JM
    Psychopharmacol Bull; 1998; 34(2):207-9. PubMed ID: 9641002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study.
    Pollack MH; Worthington JJ; Otto MW; Maki KM; Smoller JW; Manfro GG; Rudolph R; Rosenbaum JF
    Psychopharmacol Bull; 1996; 32(4):667-70. PubMed ID: 8993089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release.
    Pae CU; Masand PS; Marks DM; Krulewicz S; Han C; Peindl K; Mannelli P; Patkar AA
    World J Biol Psychiatry; 2009; 10(4 Pt 2):435-41. PubMed ID: 19382010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
    Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
    Sheehan DV; McElroy SL; Harnett-Sheehan K; Keck PE; Janavs J; Rogers J; Gonzalez R; Shivakumar G; Suppes T
    J Affect Disord; 2009 Jun; 115(3):376-85. PubMed ID: 19042026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study.
    Bares M; Kopecek M; Novak T; Stopkova P; Sos P; Kozeny J; Brunovsky M; Höschl C
    J Affect Disord; 2009 Nov; 118(1-3):94-100. PubMed ID: 19249105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.